Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients

Kazuyuki Matsumoto, Yasuhiro Miyake, Hironari Katou, Hirofumi Kawamoto, Atsushi Imagawa, Tatsuya Toyokawa, Morihito Nakatsu, Masaharu Ando, Mamoru Hirohata, Kazuhide Yamamoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aims: The efficacy of gemcitabine (GEM) on unresectable pancreatic cancer has been reported. However, in elderly patients, severe toxicities are frequently observed. In this study we aimed to assess the efficacy of low-dose GEM on unresectable pancreatic cancer in elderly patients. Methods: We reviewed 68 elderly patients (≥65 years) with unresectable pancreatic cancer. Thirty-six patients were treated with low-dose GEM (600-800 mg/m 2; GEM group), and the other 32 received best supportive care (BSC group). Results: Median survival was 7.6 and 2.3 months in the GEM and BSC groups, respectively. In the GEM group, the median survival period was longer in 24 patients showing partial response or stable disease than in 12 patients showing progressive disease (11.4 vs. 5.3 months). Furthermore, the patients showing progressive disease had better 6-month survival than patients in the BSC group. Thirteen patients (36%) developed severe toxicities (grade 3 or 4). Low-dose GEM, stage of disease and performance status were associated with the prognosis. Conclusions: Low-dose GEM may improve the prognosis of elderly patients with unresectable pancreatic cancer. Furthermore, frequencies of severe toxicity seem lower in patients treated with low-dose GEM compared with previous reports.

Original languageEnglish
Pages (from-to)230-235
Number of pages6
JournalDigestion
Volume84
Issue number3
DOIs
Publication statusPublished - Oct 2011

Fingerprint

gemcitabine
Pancreatic Neoplasms
Survival

Keywords

  • Age
  • Best supportive care
  • Gemcitabine
  • Pancreatic cancer
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Matsumoto, K., Miyake, Y., Katou, H., Kawamoto, H., Imagawa, A., Toyokawa, T., ... Yamamoto, K. (2011). Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Digestion, 84(3), 230-235. https://doi.org/10.1159/000330384

Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. / Matsumoto, Kazuyuki; Miyake, Yasuhiro; Katou, Hironari; Kawamoto, Hirofumi; Imagawa, Atsushi; Toyokawa, Tatsuya; Nakatsu, Morihito; Ando, Masaharu; Hirohata, Mamoru; Yamamoto, Kazuhide.

In: Digestion, Vol. 84, No. 3, 10.2011, p. 230-235.

Research output: Contribution to journalArticle

Matsumoto, K, Miyake, Y, Katou, H, Kawamoto, H, Imagawa, A, Toyokawa, T, Nakatsu, M, Ando, M, Hirohata, M & Yamamoto, K 2011, 'Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients', Digestion, vol. 84, no. 3, pp. 230-235. https://doi.org/10.1159/000330384
Matsumoto, Kazuyuki ; Miyake, Yasuhiro ; Katou, Hironari ; Kawamoto, Hirofumi ; Imagawa, Atsushi ; Toyokawa, Tatsuya ; Nakatsu, Morihito ; Ando, Masaharu ; Hirohata, Mamoru ; Yamamoto, Kazuhide. / Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. In: Digestion. 2011 ; Vol. 84, No. 3. pp. 230-235.
@article{f9febf4903ca4b5eadb58063dffcc1f1,
title = "Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients",
abstract = "Background/Aims: The efficacy of gemcitabine (GEM) on unresectable pancreatic cancer has been reported. However, in elderly patients, severe toxicities are frequently observed. In this study we aimed to assess the efficacy of low-dose GEM on unresectable pancreatic cancer in elderly patients. Methods: We reviewed 68 elderly patients (≥65 years) with unresectable pancreatic cancer. Thirty-six patients were treated with low-dose GEM (600-800 mg/m 2; GEM group), and the other 32 received best supportive care (BSC group). Results: Median survival was 7.6 and 2.3 months in the GEM and BSC groups, respectively. In the GEM group, the median survival period was longer in 24 patients showing partial response or stable disease than in 12 patients showing progressive disease (11.4 vs. 5.3 months). Furthermore, the patients showing progressive disease had better 6-month survival than patients in the BSC group. Thirteen patients (36{\%}) developed severe toxicities (grade 3 or 4). Low-dose GEM, stage of disease and performance status were associated with the prognosis. Conclusions: Low-dose GEM may improve the prognosis of elderly patients with unresectable pancreatic cancer. Furthermore, frequencies of severe toxicity seem lower in patients treated with low-dose GEM compared with previous reports.",
keywords = "Age, Best supportive care, Gemcitabine, Pancreatic cancer, Prognosis, Survival",
author = "Kazuyuki Matsumoto and Yasuhiro Miyake and Hironari Katou and Hirofumi Kawamoto and Atsushi Imagawa and Tatsuya Toyokawa and Morihito Nakatsu and Masaharu Ando and Mamoru Hirohata and Kazuhide Yamamoto",
year = "2011",
month = "10",
doi = "10.1159/000330384",
language = "English",
volume = "84",
pages = "230--235",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients

AU - Matsumoto, Kazuyuki

AU - Miyake, Yasuhiro

AU - Katou, Hironari

AU - Kawamoto, Hirofumi

AU - Imagawa, Atsushi

AU - Toyokawa, Tatsuya

AU - Nakatsu, Morihito

AU - Ando, Masaharu

AU - Hirohata, Mamoru

AU - Yamamoto, Kazuhide

PY - 2011/10

Y1 - 2011/10

N2 - Background/Aims: The efficacy of gemcitabine (GEM) on unresectable pancreatic cancer has been reported. However, in elderly patients, severe toxicities are frequently observed. In this study we aimed to assess the efficacy of low-dose GEM on unresectable pancreatic cancer in elderly patients. Methods: We reviewed 68 elderly patients (≥65 years) with unresectable pancreatic cancer. Thirty-six patients were treated with low-dose GEM (600-800 mg/m 2; GEM group), and the other 32 received best supportive care (BSC group). Results: Median survival was 7.6 and 2.3 months in the GEM and BSC groups, respectively. In the GEM group, the median survival period was longer in 24 patients showing partial response or stable disease than in 12 patients showing progressive disease (11.4 vs. 5.3 months). Furthermore, the patients showing progressive disease had better 6-month survival than patients in the BSC group. Thirteen patients (36%) developed severe toxicities (grade 3 or 4). Low-dose GEM, stage of disease and performance status were associated with the prognosis. Conclusions: Low-dose GEM may improve the prognosis of elderly patients with unresectable pancreatic cancer. Furthermore, frequencies of severe toxicity seem lower in patients treated with low-dose GEM compared with previous reports.

AB - Background/Aims: The efficacy of gemcitabine (GEM) on unresectable pancreatic cancer has been reported. However, in elderly patients, severe toxicities are frequently observed. In this study we aimed to assess the efficacy of low-dose GEM on unresectable pancreatic cancer in elderly patients. Methods: We reviewed 68 elderly patients (≥65 years) with unresectable pancreatic cancer. Thirty-six patients were treated with low-dose GEM (600-800 mg/m 2; GEM group), and the other 32 received best supportive care (BSC group). Results: Median survival was 7.6 and 2.3 months in the GEM and BSC groups, respectively. In the GEM group, the median survival period was longer in 24 patients showing partial response or stable disease than in 12 patients showing progressive disease (11.4 vs. 5.3 months). Furthermore, the patients showing progressive disease had better 6-month survival than patients in the BSC group. Thirteen patients (36%) developed severe toxicities (grade 3 or 4). Low-dose GEM, stage of disease and performance status were associated with the prognosis. Conclusions: Low-dose GEM may improve the prognosis of elderly patients with unresectable pancreatic cancer. Furthermore, frequencies of severe toxicity seem lower in patients treated with low-dose GEM compared with previous reports.

KW - Age

KW - Best supportive care

KW - Gemcitabine

KW - Pancreatic cancer

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=80051787562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051787562&partnerID=8YFLogxK

U2 - 10.1159/000330384

DO - 10.1159/000330384

M3 - Article

C2 - 21860243

AN - SCOPUS:80051787562

VL - 84

SP - 230

EP - 235

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 3

ER -